Clinical trial
Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery…
NCT00368797 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00368797 |
|---|---|
| Title | Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease |
| Official title | A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease. |
| Acronym | TALISMAN 201 |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Peripheral Arterial Disease |
| Intervention type | Drug |
| Interventions | XRP0038 (NV1FGF) |
| Enrollment | 125 |
| Start date | Mar 1, 2002 |
| Primary completion | Apr 1, 2005 |
| Completion | Apr 1, 2005 |
| First posted | Aug 25, 2006 |
| Last update posted | Nov 18, 2008 |
| Countries | Belgium, France, Germany, Italy, Switzerland, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: